share_log

Exicure | 10-Q: Q2 2024 Earnings Report

Exicure | 10-Q: Q2 2024 Earnings Report

Exicure | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/14 04:35

Moomoo AI 已提取核心信息

Exicure reported Q2 2024 financial results with a net loss of $0.6 million compared to $5.8 million in Q2 2023. Revenue included $0.5 million from a patent license agreement and $0.6 million from sample sales. Cash and cash equivalents stood at $0.5 million as of June 30, 2024, down from $0.8 million at year-end 2023.The company continues exploring strategic alternatives after suspending all research and development activities. Management is attempting to license intellectual property and seeking potential partners for transactions. A recent patent license agreement was executed in February 2024 for developing cavrotolimod for hepatitis treatment, generating an upfront payment of $0.5 million.Facing substantial doubt about its ability to continue as a going concern, Exicure requires significant near-term funding to maintain operations. The company received notice from Nasdaq regarding listing compliance issues and must meet all requirements by September 16, 2024. Management is working to address these concerns through potential reverse stock split and other measures while pursuing strategic options to maximize shareholder value.
Exicure reported Q2 2024 financial results with a net loss of $0.6 million compared to $5.8 million in Q2 2023. Revenue included $0.5 million from a patent license agreement and $0.6 million from sample sales. Cash and cash equivalents stood at $0.5 million as of June 30, 2024, down from $0.8 million at year-end 2023.The company continues exploring strategic alternatives after suspending all research and development activities. Management is attempting to license intellectual property and seeking potential partners for transactions. A recent patent license agreement was executed in February 2024 for developing cavrotolimod for hepatitis treatment, generating an upfront payment of $0.5 million.Facing substantial doubt about its ability to continue as a going concern, Exicure requires significant near-term funding to maintain operations. The company received notice from Nasdaq regarding listing compliance issues and must meet all requirements by September 16, 2024. Management is working to address these concerns through potential reverse stock split and other measures while pursuing strategic options to maximize shareholder value.
Exicure报告了2024年第二季度的财务结果，净亏损为60万美元，而2023年第二季度的净亏损为580万美元。营业收入包括来自专利许可协议的50万美元和样品销售的60万美元。截至2024年6月30日，现金及现金等价物为50万美元，较2023年年末的80万美元有所下降。在暂停所有研究和开发活动后，公司继续探索战略选择。管理层正试图进行知识产权许可，并寻求潜在的交易合作伙伴。最近在2024年2月执行了一项专利许可协议，用于开发cavrotolimod治疗肝炎，产生了50万美元的预付款。面对持续经营能力的重大疑虑，Exicure需要大量短期资金以维持运营。公司收到纳斯达克关于上市合规问题的通知，必须在2024年9月16日之前满足所有要求。管理层正努力通过潜在的反向股票拆分和其他措施来解决这些问题，同时追求战略选择以最大化股东价值。
Exicure报告了2024年第二季度的财务结果，净亏损为60万美元，而2023年第二季度的净亏损为580万美元。营业收入包括来自专利许可协议的50万美元和样品销售的60万美元。截至2024年6月30日，现金及现金等价物为50万美元，较2023年年末的80万美元有所下降。在暂停所有研究和开发活动后，公司继续探索战略选择。管理层正试图进行知识产权许可，并寻求潜在的交易合作伙伴。最近在2024年2月执行了一项专利许可协议，用于开发cavrotolimod治疗肝炎，产生了50万美元的预付款。面对持续经营能力的重大疑虑，Exicure需要大量短期资金以维持运营。公司收到纳斯达克关于上市合规问题的通知，必须在2024年9月16日之前满足所有要求。管理层正努力通过潜在的反向股票拆分和其他措施来解决这些问题，同时追求战略选择以最大化股东价值。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点